Kornimate/medical-research-clean huggingface dataset:
dose-response of adenosine for perioperative pain

Conditions: Perioperative Pain

Summary: adenosine a1 and a2 receptors are widely distributed in the brain and spinal cord and represent a non-opiate target for pain management. activated spinal a1 receptors inhibit sensory transmission by inhibiting the slow ventral root potential, which is the c-fiber-evoked excitatory response associated with nociception. adenosine may inhibit intrinsic neurons through an increase in k+ conductance and presynaptic inhibition of sensory nerve terminals to inhibit the release of substance p and perhaps glutamate. although adenosine a3 receptors are not found in the nervous system, adenosine is also known to have anti-inflammatory properties that may contribute to pain relief in the peripheral setting of inflammation.


Eligibility criteria:
inclusion criteria: * female gender; age 18 to 65 years; * american society of anesthesiology (asa) physical classification i to iii; * scheduled for non-emergent abdominal hysterectomy (with or without salpingo-oophorectomy) or myomectomy under general anesthesia; exclusion criteria: * asa physical classification of iv or v; * documented history of cardiovascular disease including coronary artery disease, uncontrolled hypertension, aortic stenosis, congestive heart failure, cardiac arrhythmias or conduction defects greater that first degree atrioventricular (av) block, sinoatrial (sa) or av node disease including sick sinus syndrome or symptomatic bradycardia, presence of devices including pacemakers or internal defibrillators, or history of symptoms consistent with any of the aforementioned conditions (e.g., angina, dyspnea on exertion, paroxysmal nocturnal dyspnea); * history of asthma, bronchospastic lung disease, or hyper-reactive airway disease; * history of gout;
adjunct episcleral brachytherapy for pcv

Conditions: Age-Related Macular Degeneration; Polypoid Choroidal Vasculopathy

Summary: this study is investigating the use of episcleral brachytherapy (esb) adjunct to aflibercept compared to aflibercept monotherapy for the treatment of polyploid choroidal vasculopathy (pcv) in patients experiencing an inadequate response to anti-vegf monotherapy.


Eligibility criteria:
inclusion criteria: * active pcv due to namd * incomplete response to anti-vegf * received at least 3 consecutive and sequential anti-vegf injections (no missed treatments) * ability to undergo esb intervention exclusion criteria: * sub-retinal fibrosis * type i or type ii diabetes mellitus * previous therapeutic radiation to the head or neck that may have resulted in radiation dose to the retina * study eye with bcva of worse than 20 etdrs letters (20/400 snellen) * fellow eye with worse bcva than the study eye or other vision-threatening disease not eligible for treatment * receiving anti-vegf therapy for any reason other than amd
a phase 1 study of vg-3927 in healthy adults and patients with alzheimer's disease

Conditions: Healthy; Alzheimer Disease

Summary: a phase 1, first-in-human, randomized, double-blind, placebo-controlled, single and multiple ascending dose study in healthy adults and open-label single dose study in patients with alzheimer's disease to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of vg-3927.


Eligibility criteria:
inclusion criteria: * the participant is deemed healthy by the principal investigator, as determined by prestudy medical evaluation * the participant voluntarily agrees to participate in this study and signs an institutional review board approved informed consent exclusion criteria: * the participant has any concurrent disease or condition that, in the opinion of the principal investigator, would make the participant unsuitable for participation in the clinical study
a genetic and perfusion study of response to cognitive enhancers in lewy body disease

Conditions: Lewy Body Disease

Summary: lewy body spectrum disorders are a common group of neurodegenerative diseases that cause memory loss, behavioural and motor disabilities that impair quality of life. cognitive enhancers help people afflicted with these conditions. however, some people do not benefit from this treatment, while others experience serious side effects. side effects and poor response lead to hospitalization and early institutionalization. pharmacogenomics, the study of how dna variation can influence drug effects, will be combined with functional changes in brain imaging in response to cognitive enhancers in patients with lewy body disease. the goal is to develop a predictive test that can be administered in the clinic to aid physicians' choice of initial medication. this can reduce health care costs and improve treatment to canadians suffering from these devastating disorders.


Eligibility criteria:
inclusion criteria: * inclusion criteria for patients with a lewy body spectrum disorder includes: age \> 50 years; and mild-moderate dementia (mini-mental state exam \[mmse\] \> 9); contact on at least four of seven days/week with a responsible caregiver; hoehn \& yahr stage ≤ 4. exclusion criteria: * age \ 4.

Keywords: pharmacogenomics dementia with lewy bodies adverse events polymorphisms acetylcholinesterase parkinson's disease dementia cognitive enhancers clinical efficacy cytochrome p450 butyrylcholinesterase
multicenter, phase i/ii study to evaluate the safety, tolerability, pk and efficacy of sct520ff in patients with namd (phase i portion)

Conditions: NAMD

Summary: multicenter, open-label, multi-dose study to evaluate the safety and tolerability in patients with namd treated with sct520ff.


Eligibility criteria:
inclusion criteria: 1. signed informed consent form. 2. age≥45 years, ≤80 years，male or femal. 3. the study eye must meet the following criteria: diagnosis of namd;active mnv lesions secondary to namd; total area of all types of lesions ≤12 optic disc areas; bcva of the study eye 73\~19 letters. exclusion criteria: 1. macular-related retinal pigment epithelial tears in the study eye; scar, fibrosis, atrophy or dense subfoveal exudation involving the fovea in the study eye. 2. significant apd or opacity of the refractive medium and miosis in the study eye that affect visual acuity or fundus examination. 3. aphakia (except intraocular lens) or posterior capsular rupture of the lens in the study eye. 4. the study eye has any eye diseases or medical history other than namd that may affect central vision and/or macular examine. 5. mnv caused by non-namd exists in the study eye . 6. active inflammation or infection in either eye before randomization. 7. known allergy to any component of the study intervention or history of allergy to fluorescein or indocyanine green, any anesthetics or antimicrobial agents used during the course of the study. 8. abnormal liver and kidney function. 9. poorly-controlled blood pressure before randomization. 10. history of a cardiovascular and cerebrovascular events, including myocardial infarction, unstable angina pectoris, cerebrovascular accidents (including tia), other thromboembolic diseases (such as thromboembolic angiitis, etc) within 6 months before randomization. 11. evidence of significant uncontrolled concomitant diseases. 12. participated in any drug (other than vitamins and minerals) or device clinical trials within 3 months or the duration of 5 half-lives of the study drug (which is longer) before randomization and have used the test drug or received device treatment. 13. pregnant, lactating women who can not take contraceptive measures during the trial.
ga-68 fapi pet before immunotherapy

Conditions: Mesotheliomas Pleural

Summary: it is aimed to evaluate fap expression and its success in predicting treatment response before immunotherapy used in the treatment of malignant mesothelioma with ga68 fapi pet/ct imaging, which allows in vivo evaluation of fap expression, which is thought to be associated with immunosuppression and resistance to immunotherapy.

patients diagnosed with pleural mesothelioma and planned for immunotherapy will be included in the study. patients will undergo ga68 fapi pet/ct imaging within 10 days before the start of immunotherapy treatment, and suvmax, suvmean, metabolic tumor volume and total ga68 fapi uptake parameters will be obtained from the tumors. following this, the routine treatment and follow-up of the patients will be carried out by their clinicians. it will be evaluated whether there is a correlation between treatment response and initial ga-68 fapi pet findings.

Eligibility criteria:
inclusion criteria: * having a histopathologically confirmed diagnosis of * pleural mesolthelioma * patients scheduled for immunotherapy with anti-pdl-1 and/or anti-ctla-4 antibodies as first or second line therapy * patients who gave informed consent form to participate in the study exclusion criteria: * ecog\>2 * patients who did not provide informed consent form to participate in the study
comparison of cyanocobalamin in avocado oil cream with steroid combination ointment

Conditions: Plaque Psoriasis

Summary: a randomized clinical trial with two groups. group a group b group a is being treated with conventional steroid combination ointment for the treatment of chronic plaque psoriasis. group b is being treated with cyanocobalamin in avocado oil cream for the treatment of chronic plaque psoriasis. each group having 45 patients.

outcome is being measured by pasi score calculation with monthly follow up.

Eligibility criteria:
inclusion criteria: * age bracket (18-60 years) * non psoriatic arthritis * no oral retinoids exclusion criteria: * pregnancy * malignancy * body surface area involving \>50%
treatment of abdominal abscesses with or without fibrinolysis

Conditions: Abdominal Abscess; Tissue Plasminogen Activator

Summary: the objective of this study is to evaluate the utility of fibrinolysis when draining an abdominal abscess as defined by length of stay after drainage.

the hypothesis is that fibrinolysis of a abscess will shorten hospital stay compared to drainage alone.

Eligibility criteria:
inclusion criteria: * patients under age 18 found to have an abscess in their abdomen related to perforated appendicitis that requires a drain either prior to or after appendectomy. exclusion criteria: * patients with known immune deficiency per medical record review * patients with another condition affecting surgical decision making or recovery * patients with drain unable to be placed

Keywords: abscess tpa
combination diuretic therapy for acute decompensated heart failure

Conditions: Acute Decompensated Heart Failure

Summary: patients with heart failure are often admitted to the hospital because they have accumulated excessive amounts of fluid, they become short of breath and congested with fluid. removing the excess fluid is necessary to improve the patients symptoms and reduce the risk of being re-admitted to the hospital. diuretics ("water pills") are often given through an iv to accelerate the fluid removal. furosemide is commonly used for fluid removal, however some patients do not respond well to the medication. there are other diuretics available that can work in conjunction with furosemide and increase the rate of fluid removal. the other "water pills" have slightly different mechanisms of action in the body compared to furosemide and when combined they may increase fluid removal. the investigators hypothesize that adding chlorothiazide to furosemide will result in quicker and more effective fluid removal in heart failure patients.

the investigators will randomly assign patients to receive either furosemide alone or furosemide in combination with chlorothiazide when they are admitted to the hospital with acute heart failure and excessive volume. all patients will be monitored for rate of fluid removal, improvement in symptoms, and side-effects of the medications.

Eligibility criteria:
inclusion criteria: * diagnosis of acute decompensated heart failure - by at least 1 symptom (dyspnea, exercise intolerance, weight gain, edema) and at least 1 sign (chest x-ray (cxr), elevated brain natriuretic peptide (bnp), rales, elevated jugular venous pressure (jvp)). * history of congestion heart failure (chf) with chronic loop diuretic use for at least the past 4 weeks * echocardiogram in the past 12 months (to document ejection fraction (ef)) exclusion criteria: * chronic kidney disease (ckd) or acute kidney injury (aki) - cr \>2.5 mg/dl * ventricular assist device * cardiogenic shock * need for mechanical or vasopressor support on admission * significant co-morbidities: chronic obstructive pulmonary disease, pneumonia, pulmonary embolism * history of pulmonary hypertension (pah) (world health organization (who) group i primary pah) * acute ischemia / post-intervention (coronary artery bypass graft, percutaneous coronary interventions) in the past 90 days

Keywords: heart failure acute diuretic management renal function chlorothiazide furosemide
addition of vandetanib to standard therapy pegliposomal doxorubicin (pld)

Conditions: Ovarian Cancer

Summary: this multi-centre, non-randomized open phase i/randomized phase ii study will be conducted in 70 patients (10 in phase i, 60 in phase ii) with platinum-refractory recurrent epithelial cancer of the ovary, fallopian tube or peritoneum. a total of approximately 5 national centers will participate in phase i of the study. if the starting criteria for phase ii of the study are met at the end of phase i, a total of approximately 20 national centers will participate in phase ii of the study.


Eligibility criteria:
inclusion criteria: * histopathologically documented invasive epithelial ovarian carcinoma, cancer of the fallopian tube or the peritoneum refractory to platinum-based chemotherapy or with partially platinum sensitive disease. * planned therapy with pegylated liposomal doxorubicin 50 mg/m² for recurrent platinum-refractory ovarian cancer. * patients with a progression-free-interval of 6 to 12 months after platinum-based chemotherapy are only eligible if a further course of platinum-based combination chemotherapy is not possible as judged by the investigator(s). * patients must have received at least one previous platinum- and taxane-based chemotherapy regimen. exclusion criteria: * brain metastases or spinal cord compression, unless treated at least 4 weeks before first dose and stable without steroid treatment for 10 days * any concomitant medications that may cause qtc prolongation or induce torsades de pointes or induce cyp3a4 function * treatment with mouse-antibodies in patients with evaluable disease and ca-125 progressive disease in the last 3 months. these patients are only eligible in case of measurable disease according to recist or cytological/histological proven relapse * more than two prior lines of chemotherapy. * any chemotherapy or other systemic anti-cancer therapy within four weeks prior to randomization. * radiation therapy within the last 4 weeks prior to randomization (with the exception of palliative radiotherapy

Keywords: zd6474 vandetanib zactima ovarian cancer phase i phase ii randomized safety
the psychological and social impact of pcos

Conditions: Polycystic Ovary Syndrome

Summary: the aim of the study is to assess the association between the quality of life of patients with pcos and various factors (age, bmi, socio-professional category, delay in diagnostic of pcos, infertility, hyperandrogenism, parity, history of anxiety and depression, cycles disorders). this study will be proposed to patients known to have pcos, during a follow-up consultation or a visit to a day hospital in the gynaecology department and/or a consultation in the reproductive medicine department. no-objection forms will be collected at the same time. a link will be sent by e-mail to the patient to access the online questionnaire on the wepi software and complete it after the consultation. responses to the questionnaire will be collected progressively and stored in a secure redcap file.


Eligibility criteria:
inclusion criteria: * female sex * adult patient (aged 18 or over) * able to read and write in french * diagnosed at a previous consultation as having pcos according to the rotterdam criteria (at least 2 out of 3 criteria from: * clinical signs of hyperandrogenism (hirsutism, acne, androgenic alopecia) and/or biochemical signs of hyperandrogenism (total testosterone \> 0.39 ng/ml and/or androstenedione \> 1.75 ng/ml) * ovulation disorders (infertility, oligomenorrhoea or amenorrhoea or cycle length either \ 35 days), * polymicrocystic ovaries on ultrasound (either 19 or more follicles measuring 2-9 mm in diameter and/or increased ovarian volume (\>10 cm3) and/or increased ovarian area (\> 5.5 cm²) without presence of cyst or dominant follicle.) * informed consent exclusion criteria: * patient with no health insurance cover * difficulties understanding or speaking french * computer (tablet/smartphone) and internet connection required. * refusal to take part in research * under court protection (guardianship/curatorship/privation of liberty)
inspiratory muscle strength training in adults with obesity

Conditions: Obesity

Summary: the purpose of this study is to determine whether inspiratory muscle strength training reduces blood pressure in adults with obesity.

obesity affects four-in-ten american adults and is associated with hypertension and greater all-cause mortality. irrespective of weight loss, aerobic exercise reduces arterial blood pressure (bp) and improves cardiometabolic health. however, nearly half of adults with obesity do not perform aerobic exercise because of low leisure time availability and exertional dyspnea secondary to high chest wall mass-related inspiratory muscle dysfunction. in other clinical populations, emerging data demonstrates time-efficient high-resistance inspiratory muscle strength training (imst) reduces bp and improves respiratory muscle function. therefore, the investigators will determine whether eight weeks of daily high-resistance imst reduces bp, improves respiratory muscle function, and concomitantly reduces exertional dyspnea in a randomized, double-blinded, sham-controlled (i.e., very low-resistance imst) clinical trial among adults with obesity

Eligibility criteria:
inclusion criteria: - body mass index 30 - 40 kg/m2 exclusion criteria: * not weight stable (\<5% change in body mass over the past six months) * overt cardiovascular, neurological, renal, liver, and/or metabolic illness (e.g., diabetes mellitus) * current, or history of uncontrolled, stage 2 hypertension (blood pressure \>140 / 90 mmhg; anti-hypertensive medications are permitted) * diagnosed obstructive sleep apnea * previous bariatric surgery * diagnosis or signs (e.g., values below the lower limit of normal) of overt airway disease(s) * current or recent (regular use within the past 6 months) use of tobacco or nicotine products (e.g., cigarettes, vaping) * pregnant (self-reported and confirmed via urine pregnancy test), lactating (self-reported), or post-menopausal (self-reported) females * prisoners * per the powerbreathe® company: * patients who have undergone recent abdominal surgery and those with abdominal hernia. * asthma patients who have a very low symptom perception and suffer from frequent, severe exacerbations or with an abnormally low perception of dyspnea. * if a patient is suffering from a ruptured eardrum or any other condition of the ear. * patients with marked elevated left ventricular end-diastolic volume and pressure. * patients with worsening heart failure signs and symptoms after training. * if an individual is suffering from a cold, sinusitis or respiratory tract infection, it is advised that they do not use the powerbreathe device.
the use of medical devices to monitor chronic obstructive pulmonary disease patients study breath-tracher 1

Conditions: COPD Exacerbation Acute

Summary: the proposed study will explore whether remote monitoring of a copd patient can be undertaken using a wearable medical device.

the proposed study will assess the sensitivity of a wearable device to measure the respiratory signals in copd patients, who have previously experienced hospitalisation due to exacerbation of their copd. participation in the study involves wearing a small sensor. the monitoring device will also assess the effectiveness of medication prescribed before, during, and after the copd exacerbation to see if it has a role in directing day-to-day therapy.

Eligibility criteria:
inclusion criteria: * any person aged 18 years or over. * current diagnosis of copd. * be willing and able to comply with study procedures and be available for study visits. • be able to use a 'smartphone or computer'. * be able to give written consent. * able to understand written and spoken english. exclusion criteria: * inability to give written informed consent. * known respiratory disorders are other than copd which, in the opinion of the investigator, is the main contributor to the patient's symptoms (e.g. asthma, lung cancer, sarcoidosis, and other interstitial lung diseases (ilds), tuberculosis, lung fibrosis, cystic fibrosis, and non-copd related bronchiectasis). * known history of significant systemic and other organ-related diseases, other than copd, which in the opinion of the investigator, is likely to interfere with the study or impact on subject safety (e.g. severe rheumatoid arthritis and lupus, kidney, liver, endocrine, psychological disorders). * known to be severely alpha-1-antitrypsin deficient (pi, sz or zz). * based on their medical record if there is any social violence/substance misuse. * having undergone lung surgery (e.g. lung volume reduction, lobectomy) within the last 6 months. * have cancer or other terminal condition which, in the opinion of the investigator, has a mortality of 12 months or less. • have, in the opinion of the investigator, evidence of alcohol, drug or solvent abuse. * taking high-dose oral corticosteroid medication (equivalent to daily dose of ≥10 mg of prednisolone) for more than 3 consecutive months. * pregnancy * patients already involved in an ongoing research study. * participation in an interventional clinical study within 3 months of visit 1 or participation in a study using an investigational medicinal product (imp) either in the previous 3 months or in the interval from last using the imp to 5 times its half-life. * patients with other significant lung disease, unable to consent, unable to use the technology (e.g. inability to use the data device, or complete the questionnaires), or at the clinician's discretion for other more significant medical/social reasons. * known allergy to surgical adhesive tape. * on long-term oxygen therapy. * acute exacerbation of copd within 6 weeks prior to inclusion.

Keywords: medical device remote monitoring technologies respiratory signal